CN101184839A - 用于呼吸道病毒感染的RNAi治疗 - Google Patents

用于呼吸道病毒感染的RNAi治疗 Download PDF

Info

Publication number
CN101184839A
CN101184839A CNA2006800114415A CN200680011441A CN101184839A CN 101184839 A CN101184839 A CN 101184839A CN A2006800114415 A CNA2006800114415 A CN A2006800114415A CN 200680011441 A CN200680011441 A CN 200680011441A CN 101184839 A CN101184839 A CN 101184839A
Authority
CN
China
Prior art keywords
sirna
virus
nucleic acid
rnai
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800114415A
Other languages
English (en)
Chinese (zh)
Inventor
葛青
缪克斯·库玛尔
詹姆士·安东尼·麦克斯威根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of CN101184839A publication Critical patent/CN101184839A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800114415A 2005-04-08 2006-04-07 用于呼吸道病毒感染的RNAi治疗 Pending CN101184839A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66994205P 2005-04-08 2005-04-08
US60/669,942 2005-04-08

Publications (1)

Publication Number Publication Date
CN101184839A true CN101184839A (zh) 2008-05-21

Family

ID=37087607

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800114415A Pending CN101184839A (zh) 2005-04-08 2006-04-07 用于呼吸道病毒感染的RNAi治疗

Country Status (10)

Country Link
US (1) US20100254945A1 (https=)
EP (1) EP1874802A2 (https=)
JP (1) JP2008535496A (https=)
KR (1) KR20070118703A (https=)
CN (1) CN101184839A (https=)
AU (1) AU2006235364A1 (https=)
CA (1) CA2603842A1 (https=)
NO (1) NO20075655L (https=)
NZ (1) NZ563845A (https=)
WO (1) WO2006110688A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103966212A (zh) * 2013-02-06 2014-08-06 霍晋 A型流感病毒NP基因有干扰作用的siRNA序列的设计及应用
CN105228648A (zh) * 2011-10-19 2016-01-06 哈里斯疫苗有限公司 快速产生改良的动物疫苗的方法
CN111201330A (zh) * 2017-10-09 2020-05-26 汉诺威医学院 用于人类呼吸道合胞病毒（hrsv）的诊断和疗法
WO2022199690A1 (zh) * 2021-03-26 2022-09-29 圣诺生物医药技术(苏州)有限公司 一种siRNA药物、药物组合物、siRNA-小分子药物偶联物及其应用
CN118800477A (zh) * 2024-07-11 2024-10-18 中国人民解放军军事科学院军事医学研究院 禽源性流感病毒溢出风险评估方法、设备、介质及产品

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
AU2006277679B2 (en) * 2005-03-31 2012-08-02 Ronen Kahana Creating poultry and other animals resistant to viral disease
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
US20100190842A1 (en) * 2007-04-12 2010-07-29 Alnylam Pharmaceuticals, Inc. Influenza polynucleotides, expression constructs, compositions, and methods of use
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
US20100286238A1 (en) * 2007-05-15 2010-11-11 Rivory Laurent Pierre Suppression of viruses involved in respiratory infection or disease
NZ581542A (en) * 2007-05-16 2012-02-24 Mat Malta Advanced Technologies Ltd Treatment and prevention of influenza
JP2010528619A (ja) * 2007-05-31 2010-08-26 ベクトン・ディキンソン・アンド・カンパニー インフルエンザａおよびインフルエンザｂウイルスを検出するための配列および方法
EP3000885B1 (en) 2009-12-18 2018-07-25 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
DK2631291T3 (da) 2010-10-22 2019-06-11 Olix Pharmaceuticals Inc Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf
US10059746B2 (en) 2011-04-04 2018-08-28 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
WO2013012835A2 (en) * 2011-07-18 2013-01-24 Oregon Health & Science University Sirna useful in the treatment of flavivirus infection
CA3185394A1 (en) 2011-09-02 2013-03-07 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
KR101567576B1 (ko) * 2012-05-22 2015-11-10 올릭스 주식회사 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
WO2014138792A1 (en) * 2013-03-14 2014-09-18 Commonwealth Scientific And Industrial Research Organisation Double-stranded rna
JP7027311B2 (ja) 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ，インコーポレーテッド ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
CN108779464B (zh) 2016-02-02 2022-05-17 奥利克斯医药有限公司 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
EP3800257B1 (en) * 2016-03-02 2024-05-01 The Board of Trustees of the Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
JP7049262B2 (ja) 2016-04-11 2022-04-06 オリックス ファーマシューティカルズ，インコーポレーテッド 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (en) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE
WO2019195936A1 (en) * 2018-04-10 2019-10-17 Ilkow Carolina Solange Microrna-based compositions and methods used in disease treatment
US11702709B2 (en) * 2021-02-09 2023-07-18 Pathogendx, Inc. Combinatorial microarray assay for clade variant detection
EP4562157A1 (en) * 2022-07-28 2025-06-04 New York University Targeting long non-coding rna chromr in interferon-mediated inflammation in humans
EP4527927A1 (en) * 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4876187A (en) * 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
US5011769A (en) 1985-12-05 1991-04-30 Meiogenics U.S. Limited Partnership Methods for detecting nucleic acid sequences
US5403711A (en) * 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5573907A (en) * 1990-01-26 1996-11-12 Abbott Laboratories Detecting and amplifying target nucleic acids using exonucleolytic activity
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1995014106A2 (en) 1993-11-17 1995-05-26 Id Biomedical Corporation Cycling probe cleavage detection of nucleic acid sequences
WO1995021271A1 (en) * 1994-02-07 1995-08-10 Molecular Tool, Inc. Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis
AU713667B2 (en) * 1996-04-12 1999-12-09 Phri Properties, Inc. Detection probes, kits and assays
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
US20030087851A1 (en) * 1999-01-20 2003-05-08 Biozak, Inc. Pharmaceutical composition for treating or preventing influenza, and novel oligonucleotide
US6277607B1 (en) 1999-05-24 2001-08-21 Sanjay Tyagi High specificity primers, amplification methods and kits
EP1081496A1 (en) * 1999-08-31 2001-03-07 Becton, Dickinson and Company Flow-through assay for visually detecting the presence of influenza A and B
EP1546344A4 (en) * 2002-09-18 2007-10-03 Isis Pharmaceuticals Inc EFFICIENT PRODUCTION OF TARGET RNAS USING SINGLE AND DOUBLE-STRONG OLIGOMER COMPOUNDS
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US20050008617A1 (en) * 2002-09-28 2005-01-13 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering RNA and short hairpin RNA
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US9486070B2 (en) 2012-10-10 2016-11-08 Stirworks Inc. Height-adjustable support surface and system for encouraging human movement and promoting wellness

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228648A (zh) * 2011-10-19 2016-01-06 哈里斯疫苗有限公司 快速产生改良的动物疫苗的方法
CN103966212A (zh) * 2013-02-06 2014-08-06 霍晋 A型流感病毒NP基因有干扰作用的siRNA序列的设计及应用
CN111201330A (zh) * 2017-10-09 2020-05-26 汉诺威医学院 用于人类呼吸道合胞病毒（hrsv）的诊断和疗法
WO2022199690A1 (zh) * 2021-03-26 2022-09-29 圣诺生物医药技术(苏州)有限公司 一种siRNA药物、药物组合物、siRNA-小分子药物偶联物及其应用
CN118800477A (zh) * 2024-07-11 2024-10-18 中国人民解放军军事科学院军事医学研究院 禽源性流感病毒溢出风险评估方法、设备、介质及产品
CN118800477B (zh) * 2024-07-11 2025-05-02 中国人民解放军军事科学院军事医学研究院 禽源性流感病毒溢出风险评估方法、设备、介质及产品

Also Published As

Publication number Publication date
AU2006235364A1 (en) 2006-10-19
EP1874802A2 (en) 2008-01-09
NZ563845A (en) 2010-09-30
US20100254945A1 (en) 2010-10-07
WO2006110688A3 (en) 2008-01-10
WO2006110688A2 (en) 2006-10-19
CA2603842A1 (en) 2006-10-19
NO20075655L (no) 2007-11-13
JP2008535496A (ja) 2008-09-04
WO2006110688A9 (en) 2007-03-15
KR20070118703A (ko) 2007-12-17

Similar Documents

Publication Publication Date Title
CN101184839A (zh) 用于呼吸道病毒感染的RNAi治疗
US20100144843A1 (en) Rnai therapeutic for respiratory virus infection
ES2539514T3 (es) Métodos y composiciones para expresar ARN viral de sentido negativo en células de canino
US20060160759A1 (en) Influenza therapeutic
KR20050084607A (ko) 인플루엔자 치료제
CA2613284A1 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
JP2013504311A (ja) インフルエンザウイルスの調製方法
WO2023030246A1 (zh) 一种用于治疗或预防非洲猪瘟的重组prrsv及其药物组合物
WO2021259244A1 (zh) 抑制SARS-COV-2病毒复制的shRNA及其应用
CN106132206B (zh) 鸡禽流感的大肠杆菌介导的siRNA沉默
US20090042823A1 (en) Uses of broad spectrum rnai therapeutics against influenza
CN101880677B (zh) 针对2009新甲型流感病毒多聚酶基因和核蛋白基因的siRNA序列及其应用
JP2008533990A (ja) インフルエンザ治療剤
JP2023532735A (ja) 組み換えエンテロウイルスおよびその使用
Bhattacharya et al. Detailed molecular biochemistry for novel therapeutic design against Nipah and Hendra virus: a systematic review
CN105586344B (zh) 抑制流感病毒相关基因的siRNA及其应用
HK1121182A (en) Rnai therapeutic for respiratory virus infection
JP2013236622A (ja) 細胞培養組成物、インフルエンザウイルスの生産方法、及び、インフルエンザウイルス
Uhl Cellular Conflicts Between RNA Virus and Host Biology
Cressey RNA Synthesis Initiation by the Nonsegmented Negative-Sense RNA Virus Polymerases
WO2026083945A1 (ja) Ｒｓｖ ｎタンパク質 ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用
WO2026058828A1 (ja) Ｒｓｖ ｌタンパク質 ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用
WO2026063375A1 (ja) Ｒｓｖ ｐタンパク質 ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用
Pfeffermann Characterization of the role of host factors in the paramyxovirus life cycle
Sarkar In vitro antiviral efficacy of pleconaril and ribavirin on foot and mouth disease virus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1121182

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080521

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1121182

Country of ref document: HK